TMB-355, which is given by subcutaneous injection, is a fourth- or fifth-line drug for AIDS patients who have become resistant to the drug cocktail. It passed through the hands of three companies before TaiMed Biologics bought it in 2007, and the patents are likely to be sold again in the future.
TMB-355 即是愛滋病人對雞尾酒療法產生抗藥性後的第四或第五線皮下注射治療藥物，經過 3 度轉手，2007 年才由當時的台灣宇昌公司購得授權。然而，這並非「355」專利的最後一次買賣。